Neich acquires Orbus Medical Tech
Orbus is leading Neich's research and development efforts for drug
eluting stents and other advanced technologies.
The acquisition is intended to offer the innovative therapy of Orbus' R stent design and the potentially revolutionary Genous bio-engineered surface technology, which is currently being evaluated in a clinical trial. Financial terms of the agreement were not disclosed.
The acquisition is the outcome of a long working relationship between the two companies. Neich Medical was previously Orbus' distributor for Asia Pacific and manufactures the delivery system for Orbus' R stent. The combined company will be called Orbus Neich
Orbus' development of a coronary R stent design, uses biotechnology to provide vascular health by targeting, accelerated healing. The R stent Coronary SDS is indicated for treatment of atherosclerotic or restenotic lesions
Specifically, drug-eluting stents have revolutionised the treatment of blocked arteries by using chemical coatings to prevent reclogging of the blood vessels,
It works by taking antibody-coated stents, which opens up blocked blood vessels, stimulating the body's own repair system to heal itself, preventing reclogging and blood clots.
